menu search

ENTA / Open Orphan client sees positive results in human challenge study

Open Orphan client sees positive results in human challenge study
Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' respiratory syncytial virus (RSV) antiviral candidate, EDP-938, which is being advanced by Enanta Pharmaceuticals Inc. AIM-quoted Open Orphan, which is a contract research organisation (CRO) specialising in the testing of infectious and respiratory disease products, helped facilitate the challenge trial which enrolled 178 healthy adult volunteers in an age range between 18 and 55. Read More
Posted: Feb 17 2022, 08:31
Author Name: Proactive Investors
Views: 103161

ENTA News  

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

By Business Wire
September 17, 2023

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, sma more_horizontal

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

By Seeking Alpha
August 7, 2023

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor R more_horizontal

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 7, 2023

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares more_horizontal

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

By Market Watch
June 20, 2023

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Shares of Enanta Pharmaceuticals Inc. ENTA, -0.25% gained 5% premarket on Tuesday after the biotech company released positive results from an early-ph more_horizontal

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 8, 2023

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares more_horizontal

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

By Business Wire
March 7, 2023

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small mole more_horizontal


Search within

Pages Search Results: